TearSolutions Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$766K
- Investors
-
13
TearSolutions General Information
Description
Developer of a peptide therapy designed to treat corneal and ocular surface diseases. The company offers a stable peptide that replicates the biological activity of a naturally occurring tear protein to repair corneal epithelium and sensory neurons, enabling ophthalmologists and eye care providers to promote corneal regeneration and improve ocular surface healing.
Contact Information
Website
www.tearsolutions.comCorporate Office
- 315 Old Ivy Way
- Suite 301
- Charlottesville, VA 22903
- United States
Corporate Office
- 315 Old Ivy Way
- Suite 301
- Charlottesville, VA 22903
- United States
TearSolutions Timeline
TearSolutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 01-Aug-2026 | $766K | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series B) | 21-Nov-2024 | Completed | ||||
| 5. Later Stage VC | 24-Jan-2022 | Completed | ||||
| 4. Later Stage VC (Series B2) | 26-Feb-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 06-Dec-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 10-Nov-2015 | $3M | $3M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2013 | Completed | Startup |
TearSolutions Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3-3 | ||||||||
| Series B-3-2 | ||||||||
| Series B-3-1 | ||||||||
| Series B-2-1 | ||||||||
| Series B2 | ||||||||
| Series B-1-1 | ||||||||
| Series B1 | ||||||||
| Series A-1 | 642,906 | $0.001000 | 8% | $5 | $5 | 1x | $5 | 2.34% |
| Series A | 642,906 | $0.001000 | 8% | $5 | $5 | 1x | $5 | 2.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TearSolutions Comparisons
Industry
Financing
Details
TearSolutions Competitors (12)
One of TearSolutions’s 12 competitors is Foventa Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| PulseSight Therapeutics | Venture Capital-Backed | Paris, France |
TearSolutions Patents
TearSolutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023300970-A1 | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms | Pending | 01-Jul-2022 | ||
| EP-4547221-A2 | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms | Pending | 01-Jul-2022 | ||
| EP-4547221-A4 | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms | Pending | 01-Jul-2022 | ||
| US-20260021159-A1 | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms | Pending | 01-Jul-2022 | ||
| WO-2024006653-A2 | Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms | Inactive | 01-Jul-2022 | A61K38/10 |
TearSolutions Signals
TearSolutions Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Virginia Innovation Partnership Corporation | Not-For-Profit Venture Capital | Minority | ||
| UVA LVG Seed Fund | Venture Capital | Minority | ||
| CAV Angels | Angel Group | Minority |
TearSolutions FAQs
-
When was TearSolutions founded?
TearSolutions was founded in 2013.
-
Where is TearSolutions headquartered?
TearSolutions is headquartered in Charlottesville, VA.
-
What is the size of TearSolutions?
TearSolutions has 10 total employees.
-
What industry is TearSolutions in?
TearSolutions’s primary industry is Drug Discovery.
-
Is TearSolutions a private or public company?
TearSolutions is a Private company.
-
What is TearSolutions’s current revenue?
The current revenue for TearSolutions is .
-
How much funding has TearSolutions raised over time?
TearSolutions has raised $44.1M.
-
Who are TearSolutions’s investors?
, , Virginia Innovation Partnership Corporation, UVA LVG Seed Fund, and CAV Angels are 5 of 13 investors who have invested in TearSolutions.
-
Who are TearSolutions’s competitors?
Foventa Therapeutics, EyePoint, ONL Therapeutics, Genentech, and PulseSight Therapeutics are some of the 12 competitors of TearSolutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process